Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This study is investigating the effect of switching from Flolan® to Epoprostenol for
Injection (EFI/ACT-385781A) in pulmonary arterial hypertension patients currently treated
with Flolan®. For this purpose patients being treated for at least 12 months with Flolan®
will be switched from Flolan® to EFI/ACT-385781A and followed-up for 90 days. During these 90
days safety and tolerability of EFI/ACT-385781A will closely be monitored in all treated
patients. This 90 follow-up will provide clinical evidence on the safety, tolerability,
efficacy and treatment satisfaction of switching from Flolan® to EFI/ACT-385781A in patients
with pulmonary arterial hypertension.